HucMSC-Ex alleviates inflammatory bowel disease via the lnc78583-mediated miR3202/HOXB13 pathway.
- Author:
Yuting XU
1
;
Li ZHANG
2
;
Dickson Kofi Wiredu OCANSEY
1
;
Bo WANG
1
;
Yilin HOU
3
;
Rong MEI
1
;
Yongmin YAN
1
;
Xu ZHANG
1
;
Zhaoyang ZHANG
4
;
Fei MAO
5
Author Information
- Publication Type:Journal Article
- MeSH: Chronic Disease; Colitis, Ulcerative/therapy*; Crohn Disease/epidemiology*; Diarrhea; Homeodomain Proteins; Humans; Inflammatory Bowel Diseases; Mesenchymal Stem Cells/cytology*; MicroRNAs; RNA, Long Noncoding; Recurrence; Umbilical Cord/cytology*
- From: Journal of Zhejiang University. Science. B 2022;23(5):423-431
- CountryChina
- Language:English
- Abstract: As a group of nonspecific inflammatory diseases affecting the intestine, inflammatory bowel disease (IBD) exhibits the characteristics of chronic recurring inflammation, and was proven to be increasing in incidence (Kaplan, 2015). IBD induced by genetic background, environmental changes, immune functions, microbial composition, and toxin exposures (Sasson et al., 2021) primarily includes ulcerative colitis (UC) and Crohn's disease (CD) with complicated clinical symptoms featured by abdominal pain, diarrhea, and even blood in stools (Fan et al., 2021; Huang et al., 2021). UC is mainly limited to the rectum and the colon, while CD usually impacts the terminal ileum and colon in a discontinuous manner (Ordás et al., 2012; Panés and Rimola, 2017). In recent years, many studies have suggested the lack of effective measures in the diagnosis and treatment of IBD, prompting an urgent need for new strategies to understand the mechanisms of and offer promising therapies for IBD.
